GlassScriptPhysician profile
Haley N Burk
NPI 1770988149
$1,807.16
in general payments reported to CMS, 2019-2025
26 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $480 · 2022: $426 · 2023: $388 · 2024: $333 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $335.77 | 2021-2025 | |
| Pfizer INC. | $236.16 | 2023-2025 | |
| Novo Nordisk INC | $221.07 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Myovant Sciences INC. | $195.51 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $143.60 | 2021 | |
| Lilly USA, LLC | $142.90 | 2021-2024 | Mounjaro, Zepbound |
| Amgen INC. | $75.18 | 2023 | Otezla, Repatha, Evenity |
| Scynexis, INC. | $50.70 | 2022 | |
| Exact Sciences Corporation | $49.84 | 2023-2024 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $48.44 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.92 | 2024-2025 | Airsupra |
| Shield Therapeutics INC | $30.01 | 2022-2023 | Accrufer |
| Lupin INC. | $28.60 | 2021 | |
| Corium, LLC | $24.89 | 2023 | Azstarys |
| Astellas Pharma US INC | $23.47 | 2024 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.30 | 2025 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $17.12 | 2021 | |
| Mission Pharmacal Company | $16.94 | 2022 | |
| Boston Scientific Corporation | $15.97 | 2025 | General - Therapies |
| Philips North America LLC | $14.94 | 2025 | Ecc Solutions |
| Evofem Biosciences, INC. | $14.77 | 2021 | |
| Eisai INC. | $14.21 | 2021 | |
| Avion Pharmaceuticals | $14.01 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.34 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $13.16 | 2023 | Rexulti |
| Organon LLC | $3.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Burk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.